NON-VIRAL GENE THERAPY
Enhancing non-viral gene therapy with dbDNA™
dbDNA™ is a high-purity, enzymatic DNA vector tailored for non-viral delivery. Free from immunogenic bacterial sequences and optimised to support robust gene expression, it offers a cleaner, more consistent platform for the development of next-generation therapies.
OVERVIEW
Advancing gene therapy with scalable, high-purity DNA technology
Boosted expression and durability
With dbDNA™, achieve enhanced peak expression and sustained durability
Improved tolerability
Enhanced tolerability driven by innate sensing and dbDNA™
1
We have one non-viral gene therapy candidate in clinic
What are the benefits of non-viral gene therapy in your workflow?
dbDNA™ enables safe, scalable gene therapy production with optimised gene expression and superior regulatory compliance.
Enhanced gene expression for more effective therapies.
Eliminates bacterial sequences for genetic delivery.
Streamlined production for faster clinical timelines.
Scalable for gene therapy applications.
GMP-compliant material for regulatory approval.
Optimised vector performance for targeted treatments.
Touchlight vs competitors
Our technology offers you improved efficiency, purity, and scalability compared to conventional plasmid DNA methods, ensuring optimised gene therapy development.
RESOURCES
Learn more about dbDNA™ and its role in non-viral gene therapy development
Explore our latest research and insights into enzymatic DNA innovation and how it could enhance your non-viral gene therapy production for advanced treatments.
